<DOC>
	<DOCNO>NCT02754518</DOCNO>
	<brief_summary>This study intend measure effect valsartan/sacubitril compare baseline standard medical heart failure therapy reverse remodel use echocardiographic endocardial surface analysis technique assess change ventricular volume , function , shape . Furthermore , Metaiodobenzylguanidine ( MIBG ) scintigraphy heart mediastinum ratio use ass Left Ventricle ( LV ) volume regression risk reduction . The investigator also intend measure effect valsartan/sacubitril exercise capacity assess 6 minute walk test peak Volume Oxygen ( V02 ) cardiopulmonary exercise testing . Additionally , investigator examine impact valsartan/sacubitril functional status quality life use Kansas City Cardiomyopathy Questionnaire ( KCCQ ) Qualia Health ( novel iPhone application incorporate Fitbit technology provide `` real time '' daily 6 minute step count assess quality life use series short targeted question . The investigator also measure Brain Natriuretic Peptide ( BNP ) , N-terminal Prohormone Brain Natriuretic Peptide ( NT-proBNP ) , Rho-kinase ( biomarker associate heart failure ) level multiple time-points throughout study period .</brief_summary>
	<brief_title>Demonstration Reverse Remodeling Effects Entresto ( Valsartan/Sacubitril ) Using Echocardiography Endocardial Surface Analysis</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Males female age ≥18 year 2 . Congestive Heart Failure ( CHF ) New York Heart Association ( NYHA ) class IIIV 25 % ≤ Left Ventricular Ejection Fraction ( LVEF ) ≤40 % ( ECHO within last 6 month ) NTproBNP ≥ 600 pg/mL OR NTproBNP ≥ 400 pg/mL hospitalization heart failure within last 12 month 3 . Stable optimized angiotensinconvertingenzyme inhibitor ( ACEI ) equivalent enalapril ≥ 10 twice day ( BID ) least 4 week 4 . Stable optimized betablocker least 4 week 5 . Optimized dose aldosterone antagonist stable dose least 4 week 1 . History angioedema 2. estimate glomerular filtration rate ( eGFR ) &lt; 30 ml/min/1.73 m2 screen 3 . Serum potassium &gt; 5.2 mmol/L screen 4 . Symptomatic hypotension define Investigator , systolic blood pressure ( SBP ) &lt; 100 mmHg screen 5 . Current acute decompensated heart failure 6 . History severe pulmonary disease 7 . Active malignancy 8 . Requirement treatment angiotensinconvertingenzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>